Articles Published in 2012

Allegro Diagnostics reveals positive results of BronchoGen genomic test for lung cancer

Wednesday, October 24, 2012 11:43 AM

Allegro Diagnostics, a molecular diagnostics company based in Maynard, Mass., released positive results from the AEGIS I (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trial, which demonstrate the diagnostic accuracy of the BronchoGe genomic test in combination with bronchoscopy.

More... »

Seattle Genetics, Abbott expand antibody-drug conjugate collaboration

Wednesday, October 24, 2012 11:02 AM

Seattle Genetics, a Bothell, Wash.-based biotech focused on monoclonal antibody-based therapies for the treatment of cancer, has expanded its antibody-drug conjugate (ADC) collaboration with Abbott Laboratories, a global healthcare company.

More... »

Forest Laboratories, moksha8 form strategic alliance for Latin America

Wednesday, October 24, 2012 10:33 AM

Forest Laboratories, an international pharmaceutical company, and moksha8, a pharmaceutical company that commercializes CNS medicines in Latin America, have entered into a broad strategic alliance that will provide Forest with a commercial footprint in Latin America and give moksha8 access to Viibryd and potentially other Forest products for the Latin American market.

More... »

PFF calls for letters of intent for 2013 Young Investigator and Established Investigator awards

Wednesday, October 24, 2012 10:11 AM

The Pulmonary Fibrosis Foundation (PFF) is accepting letters of intent for its 2013 PFF Research Fund grants.  Letters of intent will be accepted until Monday, November 26.  

More... »

EMA investigates Roche's alleged non-compliance with pharmacovigilance obligations

Wednesday, October 24, 2012 09:46 AM

The European Medicines Agency (EMA) has initiated an infringement procedure against Roche Registration, following a request of the European Commission, to investigate allegations that the company has failed to comply with pharmacovigilance obligations in relation to its 19 centrally authorized medicines.

More... »

Cortex unveils growth plans, 1,400 new jobs

Wednesday, October 24, 2012 09:24 AM

Cortex, a St. Louis-based hub of bioscience and technology R&D and commercialization, has unveiled phase two of its 25-year master plan, which will bring 1,400 new jobs and 384,000 square feet of additional lab and office space to the district.

More... »

Bayer’s riociguat meets primary endpoint in phase III study in PAH

Tuesday, October 23, 2012 07:15 AM

Bayer HealthCare Pharmaceuticals, the U.S.-based pharmaceuticals business of Bayer HealthCare, issued data from the phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.

More... »

Lilly touts positive results from phase III trials of dulaglutide in T2D

Monday, October 22, 2012 01:24 PM

Global pharmaceutical company Eli Lilly released positive top-line results of three completed phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes.

More... »

Pfizer to acquire NextWave Pharmaceuticals

Monday, October 22, 2012 12:56 PM

Pfizer, a global research-based pharmaceutical company, has agreed to acquire NextWave Pharmaceuticals, a privately-held, specialty pharmaceutical company focused on attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

More... »

AMRI, Shire ink 5-year extension of API supply agreement

Monday, October 22, 2012 12:22 PM

AMRI, a global contract research and manufacturing organization, has entered into a multi-year supply agreement for an undisclosed product with Shire U.S. Manufacturing, a subsidiary of specialty biopharmaceutical company Shire.

More... »